The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
- Conditions
- Invasive Ductal Carcinoma, Breast
- Interventions
- Procedure: Cryoablation
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- Conditions
- Basal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2025-03-14
- Target Recruit Count
- 57
- Registration Number
- NCT03521830
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
- Conditions
- Prostate Cancer
- Interventions
- Other: Placebo
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2025-02-27
- Target Recruit Count
- 24
- Registration Number
- NCT03507608
- Locations
- 🇺🇸
SKCCC at Johns Hopkins, Baltimore, Maryland, United States
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Drug: 18F-NaF
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-05-07
- Target Recruit Count
- 25
- Registration Number
- NCT03497377
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function
- Conditions
- Breast CancerFatigue
- Interventions
- Other: sham transcranial direct current stimulationOther: transcranial direct current stimulation
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2021-01-15
- Target Recruit Count
- 3
- Registration Number
- NCT03487601
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-08-26
- Target Recruit Count
- 2
- Registration Number
- NCT03471286
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2025-03-10
- Target Recruit Count
- 150
- Registration Number
- NCT03471650
- Locations
- 🇺🇸
SKCCC, Baltimore, Maryland, United States
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- Conditions
- Solid Tumor, ChildhoodSarcomaSolid Tumor, Adult
- Interventions
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2025-02-10
- Target Recruit Count
- 39
- Registration Number
- NCT03465592
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸New York Medical Center/ Maria Fareri Children's Hospital, Valhalla, New York, United States
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
- Conditions
- Breast Cancer
- Interventions
- Drug: Endocrine Therapy and a CDK 4/6 inhibitor
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2025-02-13
- Target Recruit Count
- 100
- Registration Number
- NCT03439735
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
- Conditions
- Neuroendocrine TumorsCarcinoid Tumor
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-01-09
- Target Recruit Count
- 9
- Registration Number
- NCT03420521
- Locations
- 🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States